S

Sage Therapeutics
D

SAGE

7.30500
USD
0.16
(2.24%)
مغلق
حجم التداول
81,288
الربح لكل سهم
-4
العائد الربحي
-
P/E
-1
حجم السوق
449,118,318
أصول ذات صلة
    C
    CLLS
    -0.02000
    (-1.30%)
    1.52000 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    F
    FOLD
    0.09500
    (1.05%)
    9.16000 USD
    Q
    QURE
    -0.130
    (-1.00%)
    12.840 USD
    R
    RCKT
    -0.390
    (-3.59%)
    10.470 USD
    المزيد
الأخبار المقالات

العنوان: Sage Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.